Abstract
Chikungunya virus (CHIKV) is an Aedes mosquito-borne virus that has caused explosive epidemics linked to acute, chronic, and severe clinical outcomes. Since 2014, Brazil has had the highest number of chikungunya fever (CHIKF) cases in the Americas. Here, we report and contextualize the spatiotemporal dynamic of CHIKF in Brazil and combine genomic, epidemiological, and vector analyses to investigate CHIKF recurrence in several Brazilian states. From 2013 to 2022, CHIKV caused seven epidemic waves across Brazil, affecting 59.5% (3,316 of 5,570) of the country’s municipalities. To date, Ceará State in the northeast has been the most affected, with 81,274 cases during the two largest epidemic waves in 2016 and 2017, and the ongoing third wave in 2022. The 2022 CHIKF recurrence was associated with a new introduction of an East/Central/South African strain. Also, the CHIKV recurrences in Ceará, Tocantins, and Pernambuco States were limited to municipalities with few or no prior reported cases in the previous epidemic waves, suggesting that spatial heterogeneity of CHIKV spread and population immunity may explain the recurrence pattern in the country. In addition, the population density metrics of main CHIKV vector in Brazil, Ae. aegypti, were not correlated spatially with locations of CHIKF recurrence in Ceará and Tocantins States. Also, we show that CHIKF disproportionally affected females, and we estimated the case-fatality ratio in Ceará at ∼1.3 deaths per 1,000 cases. These findings more comprehensively describe CHIKV epidemics in Brazil and contribute to understanding CHIKF recurrence in urban settings. Overall, this information may help guide public health policy to mitigate and reduce the burden of urban arboviruses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
WMS is supported by a Global Virus Network fellowship and Burroughs Wellcome Fund - Climate change and human health seed grants (#1022448). SCW is supported by National Institutes of Health grant AI12094. This project was supported by the Medical Research Council and FAPESP - Brazil-UK Centre for (Arbo)virus Discovery, Diagnosis, Genomics, and Epidemiology partnership award (MR/S0195/1 and FAPESP 2018/14389-0). NC acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme by the European Union. NRF is supported by a Wellcome Trust and Royal Society Sir Henry Dale Fellowship (grant no. 204311/Z/16/Z). JLPM is supported by National Council for Scientific and Technological Development (CNPq), grant no 305628/2020-8. MRA and PPB were supported by Coordination for the Improvement of Higher Education Personnel scholarships (CAPES# 88887.356527/2019-00 and 88887.661921/2022-00). DATT is supported by CNPq scholarship (#141844/2019-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the ethics committees from the University of Campinas, Brazil (approval number #53910221.0.0000.5404).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All statistical computing analyses were conducted using the R project. No custom code was developed. New sequences have been deposited in GenBank with accession numbers (will be made available upon acceptance of the publication).
